本帖最后由 老马 于 2013-3-13 13:43 编辑
2 e4 h% E0 b: Y% c" V9 C+ R! h: x! I
健择（吉西他滨）+顺铂+阿瓦斯汀+ P0 q8 c( z# A2 S0 ?' `& a
Gemzar +Cisplatin + Avastin
- D2 c& i% { a. b+ a* u! thttp://annonc.oxfordjournals.org/content/21/9/1804.full+ e) F3 E ?4 q7 |+ K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% h" u' {# k( y: `# S8 M7 \, wPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ D! X/ T/ j9 }; o: W) C# JResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* z( u) f* v. v& z4 o% _4 W* Z. y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 610)
3 X- f- }9 s* g: A: P* a华为网盘附件：, @+ R, `5 ]$ Y# ?+ |2 _& e. h. q
【华为网盘】ava.JPG
! X& F7 J* c7 b2 q2 g |
显身卡
